A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
